Published in Blood on November 19, 2007
Dual targeting strategies with bispecific antibodies. MAbs (2012) 2.13
Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol Sci (2009) 2.04
Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov (2013) 1.35
Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood (2009) 0.99
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem (2010) 0.97
Investigational immunotherapeutics for B-cell malignancies. J Clin Oncol (2010) 0.88
The making of bispecific antibodies. MAbs (2017) 0.84
Induction of apoptosis by cross-linking antibodies bound to human B-lymphoma cells: expression of Annexin V binding sites on the antibody cap. Cancer Biother Radiopharm (2009) 0.79
Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. MAbs (2015) 0.77
The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone. Cancer Immunol Immunother (2011) 0.76
Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor. J Cell Commun Signal (2016) 0.76
"Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A (1993) 2.91
A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med (1999) 2.42
Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol (1997) 2.13
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol (2003) 2.05
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res (2004) 2.00
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res (2003) 1.61
CD22 associates with the human surface IgM-B-cell antigen receptor complex. Proc Natl Acad Sci U S A (1993) 1.60
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A (2006) 1.50
Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans (1997) 1.45
Formation of a bispecific antibody by the use of leucine zippers. J Immunol (1992) 1.37
Highly efficient and simple methods for the preparation of peroxidase and active peroxidase-antibody conjugates for enzyme immunoassays. Anal Biochem (1984) 1.36
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol (2006) 1.35
Association of CD22 with the B cell antigen receptor. Eur J Immunol (1993) 1.35
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol (2005) 1.34
Crystal structure of a diabody, a bivalent antibody fragment. Structure (1994) 1.32
Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem (1998) 1.26
Transient translocation of the B cell receptor and Src homology 2 domain-containing inositol phosphatase to lipid rafts: evidence toward a role in calcium regulation. J Immunol (2000) 1.24
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol (2006) 1.23
Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol (2005) 1.21
Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol (2005) 1.20
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res (2004) 1.16
Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol Med (2005) 1.12
Immunotherapy of Non-Hodgkin's lymphomas. Hematology Am Soc Hematol Educ Program (2001) 1.12
Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol Immunother (1993) 1.10
Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer (2004) 1.07
Construction, expression, and activity of a bivalent bispecific single-chain antibody. J Biol Chem (1994) 1.06
Entry of B cell receptor into signaling domains is inhibited in tolerant B cells. J Exp Med (2000) 1.04
Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther (2006) 1.01
Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Mol Immunol (1995) 0.99
Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res (1989) 0.99
The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. Cell Immunol (1989) 0.97
Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res (2002) 0.96
Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology (N Y) (1993) 0.95
Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. Int Immunopharmacol (2004) 0.93
B cell antigen receptor and CD40 differentially regulate CD22 tyrosine phosphorylation. J Immunol (2006) 0.90
Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer (1994) 0.87
Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Ther Immunol (1994) 0.87
Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett (1999) 0.84
Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens. Mol Immunol (2000) 0.83
Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma. Int J Cancer (2003) 0.81
Synthetic glycan ligand excludes CD22 from antigen receptor-containing lipid rafts. Biochem Biophys Res Commun (2007) 0.80
New developments in immunotherapy for non-Hodgkin's lymphoma. Curr Oncol Rep (2005) 0.79
Di-diabody: a novel tetravalent bispecific antibody molecule by design. J Immunol Methods (2003) 0.79
Activation of Bad trafficking is involved in the BCR-mediated apoptosis of immature B cells. Apoptosis (2006) 0.79
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol (2006) 2.79
A novel method of 18F radiolabeling for PET. J Nucl Med (2009) 2.35
Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: a double-blind, placebo controlled, randomized study. J Urol (2010) 2.17
PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res (2007) 2.06
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol (2003) 2.05
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res (2004) 2.00
Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol (2005) 1.83
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther (2006) 1.82
Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood (2013) 1.78
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med (2006) 1.77
Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem (2010) 1.76
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol (2008) 1.75
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood (2009) 1.72
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med (2005) 1.69
Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood (2012) 1.63
Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford) (2013) 1.58
Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J Nucl Med (2005) 1.57
Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res (2005) 1.56
CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res (2007) 1.51
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A (2006) 1.50
Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin (2006) 1.50
Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med (2005) 1.49
Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging (2013) 1.49
Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res (2005) 1.49
IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci U S A (2007) 1.47
A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med (2010) 1.47
New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol (2005) 1.45
Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood (2004) 1.41
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol (2006) 1.35
Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer (2007) 1.35
Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med (2007) 1.35
Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res (2002) 1.35
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol (2005) 1.34
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol (2009) 1.34
Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med Mol Imaging (2002) 1.31
Pretargeted molecular imaging and radioimmunotherapy. Theranostics (2012) 1.31
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood (2008) 1.30
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther (2006) 1.30
CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res (2004) 1.25
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol (2006) 1.23
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res (2005) 1.22
Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med (2006) 1.18
High-yielding aqueous 18F-labeling of peptides via Al18F chelation. Bioconjug Chem (2011) 1.17
Sphingolipid targets in cancer therapy. Mol Cancer Ther (2006) 1.17
Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2010) 1.17
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res (2004) 1.16
Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther (2002) 1.15
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res (2008) 1.15
Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther (2010) 1.13
Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther (2010) 1.12
Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res (2003) 1.12
177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo. Nucl Med Biol (2005) 1.12
Efficacy of an alpha1 blocker in expulsive therapy of lower ureteral stones. J Endourol (2008) 1.11
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) (2013) 1.10
The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res (2007) 1.10
Cancer radioimmunotherapy. Immunotherapy (2011) 1.10
Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat (2004) 1.10